# Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

> **NCT02370888** · PHASE1 · TERMINATED · sponsor: **University of Florida** · enrollment: 11 (actual)

## Conditions studied

- Leukemia, Myeloid
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02370888
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-16
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-05-31
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2020-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02370888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02370888, "Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02370888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*